Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandro Gozzetti

Showing results (121-130 of 212) with videos related to

Pageof 22
Sort By:
Leukemia Research|June 18, 2014
Chemoimmunotherapy with oral low-dose fludarabine, cyclophosphamide and rituximab (old-FCR) as treatment for elderly patients with chronic lymphocytic leukaemiaAlessandro Gozzetti, Veronica Candi, Alberto Fabbri, et al.
European Journal of Haematology|June 24, 2022
Carfilzomib plus dexamethasone in patients with relapsed and refractory multiple myeloma: A retro-prospective observational studyMaria Livia Del Giudice, Alessandro Gozzetti, Elisabetta Antonioli, et al.
Advances in Hematology|May 18, 2012
EBV Reactivation and Chromosomal Polysomies: Euphorbia tirucalli as a Possible Cofactor in Endemic Burkitt LymphomaSusanna Mannucci, Anna Luzzi, Alessandro Carugi, et al.
Calcified Tissue International|April 18, 2008
The effects of zoledronic acid on serum lipids in multiple myeloma patientsAlessandro Gozzetti, Luigi Gennari, Daniela Merlotti, et al.
British Journal of Haematology|February 21, 2018
Low-level TP53 mutational load antecedes clonal expansion in chronic lymphocytic leukaemiaAnna Maria Pinto, Filomena T Papa, Elisa Frullanti, et al.
Frontiers in Cell and Developmental Biology|February 23, 2024
p66Shc deficiency in CLL cells enhances PD-L1 expression and suppresses immune synapse formationLudovica Lopresti, Nagaja Capitani, Vanessa Tatangelo, et al.
Cancer|April 21, 2012
Evaluation of residual CD34(+) Ph(+) progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapyMarzia Defina, Micaela Ippoliti, Alessandro Gozzetti, et al.
Medicina (Kaunas, Lithuania)|September 28, 2021
Real-Life Experience with Pomalidomide plus Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma: A Retrospective and Prospective StudyMaria Livia Del Giudice, Alessandro Gozzetti, Elisabetta Antonioli, et al.
Pharmacological Research|November 4, 2021
A novel class of oxazepine-based anti-cancer agents induces cell death in primary human CLL cells and efficiently reduces tumor growth in Eμ-TCL1 mice through the JNK/STAT4/p66Shc axisFrancesca Vanni, Ludovica Lopresti, Vanessa Zurli, et al.
Journal of Personalized Medicine|March 25, 2022
Daratumumab in AL Amyloidosis: A Real-Life Experience of the "RTM" (Regional Tuscan Myeloma Network)Vincenzo Sammartano, Elisabetta Antonioli, Gabriele Buda, et al.
Pageof 22

Showing results (121-130 of 212) with videos related to

Sort By:
Pageof 22
Leukemia Research|June 18, 2014
Chemoimmunotherapy with oral low-dose fludarabine, cyclophosphamide and rituximab (old-FCR) as treatment for elderly patients with chronic lymphocytic leukaemiaAlessandro Gozzetti, Veronica Candi, Alberto Fabbri, et al.
European Journal of Haematology|June 24, 2022
Carfilzomib plus dexamethasone in patients with relapsed and refractory multiple myeloma: A retro-prospective observational studyMaria Livia Del Giudice, Alessandro Gozzetti, Elisabetta Antonioli, et al.
Advances in Hematology|May 18, 2012
EBV Reactivation and Chromosomal Polysomies: Euphorbia tirucalli as a Possible Cofactor in Endemic Burkitt LymphomaSusanna Mannucci, Anna Luzzi, Alessandro Carugi, et al.
Calcified Tissue International|April 18, 2008
The effects of zoledronic acid on serum lipids in multiple myeloma patientsAlessandro Gozzetti, Luigi Gennari, Daniela Merlotti, et al.
British Journal of Haematology|February 21, 2018
Low-level TP53 mutational load antecedes clonal expansion in chronic lymphocytic leukaemiaAnna Maria Pinto, Filomena T Papa, Elisa Frullanti, et al.
Frontiers in Cell and Developmental Biology|February 23, 2024
p66Shc deficiency in CLL cells enhances PD-L1 expression and suppresses immune synapse formationLudovica Lopresti, Nagaja Capitani, Vanessa Tatangelo, et al.
Cancer|April 21, 2012
Evaluation of residual CD34(+) Ph(+) progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapyMarzia Defina, Micaela Ippoliti, Alessandro Gozzetti, et al.
Medicina (Kaunas, Lithuania)|September 28, 2021
Real-Life Experience with Pomalidomide plus Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma: A Retrospective and Prospective StudyMaria Livia Del Giudice, Alessandro Gozzetti, Elisabetta Antonioli, et al.
Pharmacological Research|November 4, 2021
A novel class of oxazepine-based anti-cancer agents induces cell death in primary human CLL cells and efficiently reduces tumor growth in Eμ-TCL1 mice through the JNK/STAT4/p66Shc axisFrancesca Vanni, Ludovica Lopresti, Vanessa Zurli, et al.
Journal of Personalized Medicine|March 25, 2022
Daratumumab in AL Amyloidosis: A Real-Life Experience of the "RTM" (Regional Tuscan Myeloma Network)Vincenzo Sammartano, Elisabetta Antonioli, Gabriele Buda, et al.
Pageof 22